Plain-English translation of NCT06196996 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing allogeneic regenerative islet transplantation, a procedure where insulin-producing cells from a donor are transplanted into people with brittle type 1 diabetes—a severe form where blood sugar stays dangerously high or low despite strong insulin therapy. Researchers want to see if this transplant can safely improve blood sugar control over one year of follow-up.
Some people with type 1 diabetes have such unpredictable and severe blood sugar swings that standard insulin therapy alone doesn't work well enough, putting them at serious risk. This trial exists to find out whether transplanting new insulin-producing cells might offer a better solution.
If you qualify, you will receive a transplant of insulin-producing cells through a medical procedure. After the transplant, you'll attend follow-up visits over 12 months to have your blood sugar monitored, blood work done, and overall health checked. You'll be asked to use a blood sugar meter regularly, keep a patient log, and take immunosuppressant medications to help your body accept the transplanted cells.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China